Microcephaly-lymphedema-chorioretinopathy syndrome

Microcephaly-lymphedema-chorioretinopathy syndrome (MLCRD), also known as microcephaly-lymphedema-chorioretinal dysplasia syndrome, is a rare genetic disorder characterized by a triad of primary microcephaly (abnormally small head size present at birth), lymphedema (swelling due to impaired lymphatic drainage), and chorioretinal dysplasia (abnormal development of the choroid and retina of the eye). The condition affects multiple body systems, primarily the central nervous system, the lymphatic system, and the eyes. Microcephaly is typically congenital and may be associated with mild to moderate intellectual disability, although intelligence can be normal in some affected individuals. Lymphedema most commonly affects the lower extremities and may be present at birth or develop during childhood. The chorioretinal abnormalities can include chorioretinal lacunae, retinal folds, and other dysplastic changes that may impair vision to varying degrees. This syndrome is caused by heterozygous mutations in the KIF11 gene, which encodes a kinesin motor protein (Eg5) essential for proper cell division and development. The KIF11 gene plays a critical role in mitotic spindle formation, and disruption of its function leads to the characteristic developmental abnormalities seen in this condition. Some patients may also present with additional features such as facial dysmorphism and, less commonly, cardiac or genitourinary anomalies. The phenotypic spectrum overlaps with the related condition known as chorioretinal dysplasia-microcephaly-mental retardation syndrome (CDMMR), which is now considered to be part of the same disease spectrum caused by KIF11 mutations. There is currently no cure for microcephaly-lymphedema-chorioretinopathy syndrome, and management is supportive and symptom-based. Treatment may include compression therapy and physiotherapy for lymphedema, ophthalmologic monitoring and interventions for visual impairment, and developmental support services including speech therapy and educational assistance for those with intellectual disability. Regular follow-up with a multidisciplinary team including geneticists, ophthalmologists, neurologists, and lymphedema specialists is recommended.

Common questions about Microcephaly-lymphedema-chorioretinopathy syndrome